Research | Participation in collaborative clinical studies for the treatment of MCDS

| January 2018 | The multinational consortium MCDS-therapy has been granted 5.7 Million Euro by the European Commission for the development of novel therapeutic approaches in rare skeletal disorders. Sciomics' expertise with the antibody microarray technology herein serves as a valuable tool for biomarker identification and personalized treatment monitoring. > Press release

Successful application of our discovery antibody microarrays in a study on bladder cancer:

In the study more than 100 biomarker candidates were identified for a prognosis of recurrence in non-muscle invasive bladder cancer. A  multivariate classifier was constructed that is based on the expression variation of 20 proteins and facilitates the prediction of recurrence with a sensitivity of 80% at a specificity of 100%.

Further informations: